Virta Health delivers a provider‑led, remote medical treatment that aims to sustainably reverse type 2 diabetes without medications or surgery. The company is a licensed medical provider in all 50 states and reported a 200% increase in its customer base in 2019, with new customers including Fortune 100 employers, Blue Shield of California (3.7 million members) and the U.S. Department of Veterans Affairs (covering over 1 million veterans with T2D). Its peer‑reviewed two‑year study showed diabetes reversal in a majority of completers, with 55% of two‑year completing patients eliminating diabetes‑specific medications and an 81% decline in insulin use from baseline across the population. Virta plans to invest in further prospective research to expand its treatment to other diseases and to continue product development. The company says the care delivery model is well suited to improve a range of cardiometabolic conditions. Current financial activity includes a recent Series C to support growth and research expansion. Virta Health delivers a telehealth-powered diabetes reversal program combining technology, nutrition science, and continuous care from physicians and health coaches. Its model emphasizes long-term adherence to nutritional interventions and places 100% of fees at risk based on clinical and financial outcomes. In peer‑reviewed studies the company reports that 94% of patients using insulin reduce or eliminate dosage at one year, 63% of diabetes prescriptions are eliminated, average HbA1c drops 1.3%, and weight-loss results exceed FDA benchmarks by about 150%, which Virta says can translate to an estimated $5,000 per patient per year in gross savings. The company works with over 100 employers, health plans, and government organizations, treats patients in all 50 states, and is experiencing nearly 200% year‑over‑year growth driven by large‑buyer demand. Virta will use its latest financing to accelerate research, product innovation, and commercial expansion to meet demand from employers, payers, and government. The company aims to use this momentum to make diabetes reversal available to more of the 30 million Americans struggling with type 2 diabetes. Virta Health delivers a treatment intended to safely and sustainably reverse type 2 diabetes using a provider-led Continuous Remote Care virtual platform rather than medications or surgery. The company reports strong clinical outcomes: 60% of enrolled clinical-trial patients achieved diabetes reversal at one year and 94% of insulin users reduced or eliminated insulin. Virta also reports weight-loss results that exceed the National Diabetes Prevention Program and FDA weight-loss benchmarks by nearly 150%, along with sustained improvements in blood pressure, inflammation, liver function, and BMI. For enterprise customers, Virta says it puts 100% of its fees at risk and can reduce prescription drug costs by more than 70% in year one. The business has seen over 150% year-over-year growth and has attracted more than 100 large payers across industry and government. The company plans to use new funding to scale its Continuous Remote Care delivery platform and expand R&D of evidence-based, non-pharmaceutical therapies for other metabolic conditions. Virta Health provides a clinically‑proven, technology‑enabled online treatment that safely and sustainably reverses type 2 diabetes and other chronic metabolic diseases without medications or surgery. Its Virta Treatment is delivered through an online clinic and has peer‑reviewed one‑year data showing 60% of patients achieved diabetes reversal, 94% of insulin users reduced or stopped usage, and 83% remained active in the trial. Virta reports the treatment also improves obesity, blood pressure, cardiovascular risk markers, inflammation, and insulin resistance, and estimates average medical and pharma cost savings of about $9,600 per patient in the first two years. The company has raised a $45 million Series B, bringing total equity funding to $75 million to date, and will use the proceeds to further improve outcomes and scale the treatment. Virta plans to invest in machine learning and AI, hire in product, engineering, data science, and clinical teams, and build commercial capabilities to partner with employers, health plans, and government. It remains committed to evidence‑based research through ongoing high‑quality clinical trials and enterprise deployments. Virta Health is described in the article as a U.S. startup. CG Health Ventures, a fund driven by Carlos Gallardo Piqué (a board member of pharmaceutical group Almirall), has taken a stake in Virta Health. The article says CG Health Ventures "ha entrado en el accionariado" of Virta Health, indicating an equity/shareholding investment. The article does not disclose the size or additional financial terms of the investment. CG Health Ventures had been launched two years earlier and, according to the article, had carried out seven operations to date. The investment was reported on 18/09/2017 with Expansión cited as the source.

Total raised

$373M

Funding rounds

6

Latest round

Series C

Latest activity

May 2023